<DOC>
	<DOCNO>NCT02473094</DOCNO>
	<brief_summary>A phase II , randomize study placebo versus metformin association chemotherapy capecitabine radiation neoadjuvant treatment locally advanced ( T3-4N0M0 TxN1-2M0 ) rectal carcinoma .</brief_summary>
	<brief_title>Neoadjuvant Metformin Association Chemoradiotherapy Locally Advanced Rectal Cancer</brief_title>
	<detailed_description>NEOMETRE randomize , double blind trial aim evaluate efficacy tolerability metformin association chemoradiotherapy preoperative treatment locally advanced ( T3-4N0M0 TxN1-2M0 ) rectal carcinoma . Patients eligible study submit neoadjuvant 3D radiotherapy 50,4 Gray ( Gy ) divide 25 application , association capecitabine , 825mg/m2 bid five day every week . The participant randomize daily metformin placebo chemoradiotherapy period . The primary end-point pathological complete response . The secondary end-points recurrence-free survival ( RFS ) , disease-free survival ( DFS ) , overall survival ( OS ) , local recurrence rate , overall response rate , sphincter preservation rate , quality life ( QoL ) toxicity .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>18 year old ; biopsy proven poorly differentiate carcinoma adenocarcinoma rectum ; lesion locate within 12 cm anal verge ( colonoscopy assessment ) ; ability tolerate oral treatment ; locally advance tumor , classify presence positive regional lymph node primary tumor invasion beyond serosa ( T3 T4 ) , assess MRI ; eligibility curative surgery ( distant metastasis invasion bony structure pelvis ) ; Performance Status ( PS ) Eastern Cooperative Oncology Group ( ECOG ) 02 ; adequate hematologic function ( hemoglobin ≥ 10 g / dL [ 5.6 mmol / L ] ; neutrophil count ≥ 1,500 / mm3 platelet count ≥ 100,000 / mm3 ) , adequate renal function ( serum creatinine le 1.5 time UNL ) adequate hepatic function ( bilirubin le 1.5 time UNL ; aspartate aminotransferase alanine aminotransferase less 2.5 time UNL ) ; know hypersensitivity metformin excipients ; squamous carcinoma rectum anal canal ; chronic treatment corticosteroid immunosuppressive agent ; treatment oral antidiabetic product ; distant metastasis diagnosis tumor invasion pelvic bone structure may proscribe curative intent surgery ; chronic acute infection ; use drug study four week prior randomization ; pregnant nursing patient ; prior radiotherapy pelvic region ; myocardial infarction six month prior randomization , uncontrolled ischemic heart disease ; congestive heart insufficiency New York Heart Association ( NYHA ) IIIIV .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Metformin</keyword>
	<keyword>Rectal Cancer</keyword>
	<keyword>Rectum</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Neoadjuvant</keyword>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Carcinoma</keyword>
</DOC>